These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 2872186)
21. [Determination of sulfapyridine levels in serum--a possibility for the control of dose related therapy with sulfasalazine]. Eitner K; Reinicke C; Hippius M Dtsch Z Verdau Stoffwechselkr; 1984; 44(6):282-8. PubMed ID: 6151895 [TBL] [Abstract][Full Text] [Related]
22. Inflammatory bowel disease: study of cell mediated cytotoxicity for isolated human colonic epithelial cells. Kemler BJ; Alpert E Gut; 1980 May; 21(5):353-9. PubMed ID: 7429297 [TBL] [Abstract][Full Text] [Related]
24. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Sharon P; Ligumsky M; Rachmilewitz D; Zor U Gastroenterology; 1978 Oct; 75(4):638-40. PubMed ID: 30669 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of platelet thromboxane synthetase by sulfasalazine. Stenson WF; Lobos E Biochem Pharmacol; 1983 Jul; 32(14):2205-9. PubMed ID: 6135423 [TBL] [Abstract][Full Text] [Related]
26. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. Stevens C; Lipman M; Fabry S; Moscovitch-Lopatin M; Almawi W; Keresztes S; Peppercorn MA; Strom TB J Pharmacol Exp Ther; 1995 Jan; 272(1):399-406. PubMed ID: 7815356 [TBL] [Abstract][Full Text] [Related]
28. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease. Korelitz BI; Present DH; Rubin PH; Fochios SE J Clin Gastroenterol; 1984 Feb; 6(1):27-31. PubMed ID: 6142067 [TBL] [Abstract][Full Text] [Related]
29. Peripheral blood mononuclear cells from patients with inflammatory bowel disease exhibit normal function in the allogeneic and autologous mixed leukocyte reaction and cell-mediated lympholysis. MacDermott RP; Bragdon MJ; Thurmond RD Gastroenterology; 1984 Mar; 86(3):476-84. PubMed ID: 6229444 [TBL] [Abstract][Full Text] [Related]
30. Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine. Goldstein PD; Alpers DH; Keating JP J Pediatr; 1979 Oct; 95(4):638-40. PubMed ID: 39125 [TBL] [Abstract][Full Text] [Related]
31. Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development. Peppercorn MA Ann Intern Med; 1984 Sep; 101(3):377-86. PubMed ID: 6147110 [TBL] [Abstract][Full Text] [Related]
32. Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease. Sharp ME; Wallace SM; Hindmarsh KW; Brown MA Eur J Clin Pharmacol; 1981; 21(3):243-50. PubMed ID: 6119205 [No Abstract] [Full Text] [Related]
33. Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease. Doering J; Begue B; Lentze MJ; Rieux-Laucat F; Goulet O; Schmitz J; Cerf-Bensussan N; Ruemmele FM Gut; 2004 Nov; 53(11):1632-8. PubMed ID: 15479684 [TBL] [Abstract][Full Text] [Related]
34. [Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)]. Eitner K; Hippius M; Reinicke C Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):14-9. PubMed ID: 6122556 [TBL] [Abstract][Full Text] [Related]
40. Lysis of colonic epithelial cells by allogeneic mononuclear and lymphokine activated killer cells derived from peripheral blood and intestinal mucosa: evidence against a pathogenic role in inflammatory bowel disease. Gibson PR; van de Pol E; Pullman W; Doe WF Gut; 1988 Aug; 29(8):1076-84. PubMed ID: 3261705 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]